About Contact Us Careers
Sign In

Non-Metastatic Castration Resistant Prostate Cancer Treatment Market - Top Companies and Manufacturers

  • Report ID: 2884
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Companies Dominating the Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Landscape

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Astellas Pharma Inc.
    • Clovis Oncology, Inc.
    • Johnson & Johnson Health Care Systems Inc.
    • Bayer AG
    • Orion Corporation
    • Merck & Co., Inc.
    • Novartis AG
    • AstraZeneca PLC
Browse Key Market Insights with Data Illustration:

In the News

  • Astellas Pharma Inc. to conduct clinical trials to develop cell therapy. The development pipeline of the company includes high unmet medical needs such as autoimmune & cardiovascular diseases and cancer. The cell therapy research of the company is based on pluripotent stem cells (PSC)

  • Clovis Oncology, Inc. to present data from Phase 3 trial, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy inmCRPC Associated with Homologous Recombination Deficiency (HRD)”. The trial is associated with men with metastatic castration-resistant prostate cancer.


Author Credits:  Radhika Pawar


  • Report ID: 2884
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of non-metastatic castration resistant prostate cancer treatment is estimated at USD 8.28 billion.

The non-metastatic castration resistant prostate cancer treatment market size was valued at USD 7.68 billion in 2024 and is likely to cross USD 14.13 billion by 2037, expanding at more than 4.8% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of prostate cancer and growth in the investment and R&D activities in oncology will boost the market growth.

North America industry is anticipated to dominate majority revenue share of 30% by 2037, propelled by increasing awareness about nmCRPC and the need to develop innovative cancer treatment solutions in the region.

The major players in the market are Pfizer Inc., Astellas Pharma Inc., Clovis Oncology, Inc., Johnson & Johnson Health Care Systems Inc., Bayer AG, Orion Corporation, Merck & Co., Inc., Novartis AG, AstraZeneca PLC
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample